

U-M Institutional Biosafety Committee
Draft Minutes
Approved at the December 19, 2025, IBC Meeting

Meeting Information:

Date: Friday, November 21, 2025

Time: 1:15-2:30 p.m.

Location: Via conference call (Zoom)

Voting Members Present: Matt Chapman, Wanlu Du, Chris Fenno, Janet Follo, Huiru Kopera, Joyce Lai, Daniel Lawrence, Patrick Lester, Akira Ono, Alex Rickard, Jackie Shields, John Thomas, Fei Wen, Christiane Wobus (Chair)

Voting Members Absent: Pamela Bennett-Baker, Tom Lanigan, Stephen Rapundalo, Andrew Tai

Alternate Members Present: Ingrid Bergin (alt. for Lester), Jessica Bunn (alt. for Follo), Dalis Collins (alt. for Lester), Crystal O'Donnell (alt. for Follo)

IBC Staff Members Present: Jen Harley, Michael Santiago-Castro, Alicia Trombley

Guests Present: Carolyn Kuenz, Eric Robertson, Nicoleen Boyle, Andrew Kennedy, Kathy Ignatoski, Jonah Lee, Pat Ward, Tara Bradsher, Sheya Jones

The meeting was called to order at: 1:15 p.m.

The meeting was adjourned at: 1:51 p.m.

Agenda Items:

1. Updates from the Chair – Christiane Wobus

Dr. Wobus announced that the committee will meet in person for the January 2026 IBC meeting. Jackie Shields also announced that the Biosafety Administrators Association would be holding a listening session with Kathryn Harris from NIH OSP regarding the upcoming changes to the NIH Guidelines. Jackie encouraged members of the committee to attend the session, which will be on December 4, 2025. Jackie also reminded the committee that a document titled “Comments in Response to NIH’s Strengthening and Modernizing Biosafety Oversight Initiative,” written by the Council on Government Relations, was attached to the agenda. Dr. Wobus also welcomed Sheya Jones, who recently took the position of Biosafety Manager in EHS.

2. Consideration of minutes from the previous meeting

The committee reviewed the minutes from the October 17, 2025, meeting. There were no changes recommended.

Motion: Matt Chapman moved to approve the minutes.

Second: Janet Follo seconded the motion.

Vote: All in favor.

3. Biosafety Officer Report – Janet Follo

Janet announced that she and Sheya were participating in a Big 10 biosafety and biosecurity group meeting to discuss upcoming changes NIH Guidelines. The group is planning to begin sessions in

January. Janet also stated that the U-M Biosafety Manual has gone through annual revisions without any major changes. The revised copy will be uploaded to the U-M EHS website. Janet gave the floor to Nicoleen Boyle.

Nicoleen described an incident that occurred on October 20th, 2025, and which has been reported to NIH-OSP. A research tech was working on a lab bench with a recombinant E. coli strain (Stbl3). The researcher was wearing a lab coat and gloves but was not wearing university-required safety glasses. While opening a 1.5 mL snap-cap tube, a small amount of the culture sprayed onto the researcher's face, including in and around their eye. They used the eyewash station to flush their eye for 5-10 minutes. The researcher, who was up to date on their required EHS-provided BSL2 training, made an appointment with Occupational Health Services. In their follow up with the lab, EHS reminded the lab that UM Emergency Room was an appropriate resource for follow-up medical care after business hours. They provided the lab with a copy of the Biological Exposure Response Guide and reminded the researcher and PI about the university required minimum PPE, which includes safety glasses.

4. Conflict of interest disclosure opportunity

Dr. Wobus asked committee members whether they or their labs were involved with, or were in conflict with, financially or otherwise, any items on today's agenda.

1. Christiane Wobus indicated a conflict with application IBCA00000756_AR13 for Dr. Wigginton.
2. Chris Fenno indicated a conflict with application IBCA00000889_AR06 for Dr. Rickard.
3. Alex Rickard indicated a conflict with application IBCA00000889_AR06 for Dr. Rickard and IBCA00000756_AR13 for Dr. Wigginton.
4. Huira Kopera indicated a conflict with application IBCA00000232_AR03 for Dr. Moran.

5. Applications for committee action

BSL2 Applications

The following BSL2 applications were considered and voted upon separately by the committee due to a conflict of interest. Chris Fenno chaired this portion of the meeting.

14. IBCA00000756_AR13

Wigginton, Krista – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (influenza viral vectors); BSL1 (RG1 viruses and bacteria); BSL2 (RG2 viruses); BSL2 (human- and animal-derived substances from non-human primates). No work involving biological toxins, animals, or plants.

Changes: Added new gene elements in vectorless systems (BSL2) and work with human and murine norovirus (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

Motion: Janet Follo moved to approve the (1) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Joyce Lai seconded the motion.

Vote: All in favor, with Christiane Wobus and Alex Rickard recused.

Christiane Wobus resumed chairing the meeting.

4. IBCA00000232_AR03**Moran, John – Renewal**

Current approval: BSL1 (plasmid vectors, baculoviral vectors, and vectorless systems); BSL2 (adenoviral, lentiviral, and MoLV vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added additional plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

Motion: Janet Follo moved to approve the (1) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Chris Fenno seconded the motion.

Vote: All in favor, with Huira Kopera recused.

15. IBCA00000889_AR06**Rickard, Alexander – Amendment**

Current approval: BSL2 (plasmid vectors in RG2 hosts); BSL2 (RG2 bacteria); BSL2 (human-derived substances). No work involving biological toxins, animal-derived substances, animals or plants.

Changes: Added work with RG2 fungi (BSL2) and additional RG2 bacteria (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

Motion: Joyce Lai moved to approve the (1) application listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Huira Kopera seconded the motion.

Vote: All in favor, with Chris Fenno and Alex Rickard recused.

The following BSL2 applications were considered by the committee and voted upon:

1. IBCA00000130_AR07**Mehta, Geeta – Amendment**

Current approval: BSL1 (vectorless systems, plasmid vectors and AAV vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances and animal-derived substances from swine and chickens); ABSL1 (mice administered rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, or plants.

Changes: Added work with transgenic mice (ABSL1).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

2. IBCA00000142_AR08**Chen, Grace – Renewal**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL1 (RG1 bacteria); BSL2 (Salmonella enterica (Typhimurium)); BSL1 (Lipotaechoic Acid); BSL2 (Cholera toxin and LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered mice administered LPS, vectorless systems, RG1 bacteria, Cholera toxin, or non-viable Salmonella enterica); ABSL2 for the duration (mice administered human-derived substances or Salmonella enterica). No work involving animal-derived substances or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

3. IBCA00000161_AR03

Mapp, Anna – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added an additional plasmid vector (BSL1) and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application.

4. *This application was handled separately due to a conflict of interest.*

5. IBCA00000303_AR06

Neamati, Nouri – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (mice administered rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added additional plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

6. IBCA00000349_AR07

Wang, Zhong – Renewal

Current approval: BSL1 (vectorless systems, plasmid, MoLV, and AAV vectors); BSL2 (lentiviral vectors and AAV vectors with growth control genes); BSL2 (human-derived substances); ABSL1 (transgenic mice and rabbits); ABSL1 (rodents administered MoLV vectors, mice and rabbits administered AAV vectors or vectorless systems); ABSL2 for 3 days (rodents and rabbits administered lentiviral vectors or AAV vectors with growth control genes); ABSL2 for the duration (rabbits and mice administered human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

7. IBCA00000453_AR17

Chen, Yuqing – Renewal

Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (adenovirus, lentivirus, and MoLV vectors); BSL2 (RG2 bacteria); BSL2 (LPS and Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic rodents and rabbits); ABSL1 (mice administered Diphtheria toxin, vectorless systems, or plasmid vectors; mice and rabbits administered AAV vectors, LPS or rDNA modified animal cells; rats administered plasmid vectors or rDNA modified animal cells); ABSL2 for 3 days (rodents and rabbits administered adenovirus vectors; rabbits and mice administered AAV vectors with growth control genes; rabbits administered retrovirus vectors); ABSL2 for the duration (rodents and

rabbits administered rDNA modified human cells, mice and rabbits administered human-derived substances, mice and rabbits administered RG2 bacteria). No work involving animal-derived substances or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

8. IBCA00000465_AR12

MacDougald, Ormond – Renewal

Current approval: BSL1 (plasmid vectors and AAV vectors); BSL2 (lentiviral, MMULV, adenoviral, and AAV vectors with growth control genes); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic rodents); ABSL1 (mice administered plasmid vectors, AAV vectors, or LPS); ABSL2 for 3 days (mice administered AAV vectors with growth control genes). No work involving infectious agents, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

9. IBCA00000515_AR06

Freeman, Zachary - Transgenic Animal Model Core Facility – Amendment

Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (AAV vectors with toxic or growth control genes); ABSL1 (transgenic rodents); ABSL1 (rodents administered AAV vectors, vectorless systems, or rDNA modified animal cells). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: Added work with human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

10. IBCA00000519_AR14

Huffnagle, Gary – Renewal

Current approval: BSL1 (plasmid vectors); BSL1 (RG1 bacteria); BSL2 (RG2 bacteria and fungi); BSL2 (cholera toxin and LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered cholera toxin, LPS, or RG1 bacteria); ABSL2 for the duration (mice administered RG2 bacteria or fungi). No work involving animal-derived substances or plants.

Changes: Added work with additional plasmid vectors host (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable review by one reviewer.

11. IBCA00000539_AR05

Inoki, Ken – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (MoLV and lentivirus vectors); BSL2 (human-derived substances); BSL2 (animal-derived substances: non-human primates); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, or plants.

Changes: Added additional work with additional plasmid vectors (BSL1) and human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

12. IBCA00000540_AR05

Higgins, Peter – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (Salmonella enterica (Typhimurium)); BSL2 (human-derived substances); BSL1 (animal-derived substances: swine); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered Salmonella enterica). No work involving biological toxins or plants.

Changes: Added work with helicobacter hepaticus (BSL2) with administration to mice (ABSL2 for the duration) and storage of lactobacillus and VSL3 (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

13. IBCA00000583_AR13

Hankenson, Kurt – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (adenovirus and lentivirus vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: ruminants and swine); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems); ABSL2 for 3 days (mice administered adenovirus vectors); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

14. *This application was handled separately due to a conflict of interest.*

15. *This application was handled separately due to a conflict of interest.*

16. IBCA00000958_AR06

Fu, Jianping – Amendment

Current approval: BSL1 (plasmid vectors, other non-viral vectors, and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); BSL2 (animal-derived substances: non-human primates). No work involving infectious agents, biological toxins, animals or plants.

Changes: Added work with AAV vectors (BSL1 and BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review by one reviewer.

17. IBCA00001009_AR07

Hammer, Gary – Amendment

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (lentivirus vectors and AAV vectors with tetanus toxin gene); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors or rDNA modified animal cells); ABSL2 for the duration (mice administered

human-derived substances or rDNA modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added new gene elements in AAV vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

18. IBCA00001441_AR04

Nagrath, Sunitha – Amendment

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (HIV); BSL2 (human-derived substances). No work involving biological toxins, animal-derived substances, animals or plants.

Changes: Added new gene elements in plasmid vectors (BSL1) and in lentivirus vectors (BSL2), additional human-derived substances (BSL2), animal-derived substances from swine (BSL1), transgenic mice (ABSL1), and administration of human-derived substances and rDNA-modified human-derived substances to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

19. IBCA00001527_AR03

Huang, Steven – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (Iberitoxin and Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Iberitoxin or Diphtheria toxin). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added work with non-K12 E. coli plasmid vectors (BSL1) and additional human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

20. IBCA00001611_AR03

Haus, Jacob – Renewal

Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

21. IBCA00001830_AR10

Shureiqi, Imad – Amendment

Current approval: BSL1 (vectorless systems, plasmid, and AAV vectors); BSL2 (adenoviral, lentiviral, and AAV vectors with growth control genes); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, rDNA-modified animal cells, or AAV vectors); ABSL2 for 3 days (mice administered AAV vectors with growth control genes); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added additional work with vectorless systems (BSL1) and additional transgenic mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

22. IBCA00002045_AR05

Rojas-Pena, Alvaro – Amendment

Current approval: BSL2 (RG2 bacteria); BSL1 (animal-derived substances from swine); BSL2 (human- and animal-derived substances from sheep); ABSL1 (sheep and pigs administered animal-derived substances); ABSL2 for the duration (pigs administered RG2 bacteria). No work involving rDNA, biological toxins, or plants.

Changes: Updated work with human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

23. IBCA00002232_AR06

Zhang, Qiang – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus and MoLV vectors); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin, plasmid vectors or rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

24. IBCA00002234_AR04

Welch, Joshua – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added work with additional human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

25. IBCA00002275_AR06

Rosenzweig, Anthony – Renewal

Current approval: BSL1 (vectorless systems, AAV, and plasmid vectors); BSL2 (adenoviral, lentiviral, and AAV vectors with growth control genes); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, AAV, or adenoviral vectors); ABSL2 for 3 days (mice administered adenoviral vectors or AAV vectors with growth control genes). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

26. IBCA00002304_AR06

Kaczorowski, Catherine – Amendment

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (lentivirus vectors); BSL2 (tetrodotoxin);

ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors). No work involving infectious agents, human- or animal-derived substances, or plants.

Changes: Added work with additional AAV vectors (BSL1) and human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

27. IBCA00002339_AR04

Shenoy, Anukul – Amendment

Current approval: BSL1 (vectorless systems and plasmid vectors); BSL2 (AAV vectors); BSL2 (RG2 bacteria, viruses, and fungi); BSL2 (Pertussis toxin, Diphtheria toxin, Pneumolysin, and LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, Diphtheria toxin, Pneumolysin, Pertussis toxin, LPS, or rDNA-modified animal cells); ABSL2 for 3 days (mice administered AAV vectors); ABSL2 for the duration (mice administered RG2 infectious agents or rDNA-modified RG2 bacteria). No work involving animal-derived substances or plants.

Changes: Added work with additional RG2 bacteria (BSL2) with administration to mice (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

28. IBCA00002470_AR01

Kramer, Paul – Amendment

Current approval: BSL1 (AAV vectors); BSL2 (tetrodotoxin and conotoxins); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors). No work involving infectious agents, human- or animal-derived substances, or plants.

Changes: Added additional route of administration category for administration of AAV vectors to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

29. IBCA00002527_AR03

Srinivasan, Sharan – Amendment

Current approval: BSL1 (AAV, plasmid vectors and vectorless systems); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors and vectorless systems). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described BSL2 risk mitigation practices are appropriate. Approval is contingent upon favorable re-review by one reviewer.

30. IBCA00003013

Shin, Jae Won - Initial Application

Proposed: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, rDNA-modified animal cells, or LPS). No work involving infectious agents, animal-derived substances, or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable review by one reviewer.

31. IBCA00003079**Edwards, Nicole - Initial Application**

Proposed: BSL1 (plasmid vectors and vectorless systems); BSL2 (human-derived substances); ABSL1 (transgenic frogs and mice); ABSL1 (frogs administered plasmid vectors and vectorless systems). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

32. IBCA00003081**Maduka, Chima - Initial Application**

Proposed: BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review by one reviewer.

Motion: Chris Fenno motioned to approve the (29) IBC applications listed above at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Huiru Kopera seconded the motion.

Vote: All in favor.

BSL1 Applications

The following BSL1 applications were considered by the committee and voted upon.

33. IBCA00000442_AR07**Weiland, James – Renewal**

Current approval: BSL1 (AAV vectors); BSL1 (animal-derived substances from pigs); ABSL1 (transgenic rodents and pigs); ABSL1 (rodents administered AAV vectors). No work involving infectious agents, biological toxins, human-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

34. IBCA00000546_AR03**Zhang, Haoming – Renewal**

Current approval: BSL1 (plasmid vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, animals or plants.

Changes: Added additional plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

35. IBCA00001523_AR02**Shih, Albert – Renewal**

Current approval: BSL2 (human- and animal-derived substances). No work involving rDNA, infectious agents, biological toxins, animals or plants.

Changes: Updated research goals for work with animal-derived substances (BSL1). Removed work with human-derived substances.

Discussion: Dr. Wobus requested a discussion from the committee to determine whether the work with animal-derived substances should be approved at BSL1. Patrick Lester stated that the work would consist of work with bone and soft tissues from pigs, cows, and chickens. There was no approved work with central nervous system (CNS) or gastrointestinal (GI) tissue. The committee discussed that use of certain more high-risk tissue types, such as CNS or GI tissue, would necessitate BSL2 practices. The committee agreed that BSL1 was appropriate and asked that an approval note be added to the application stating the BSL1 designation only applies to non-CNS and non-GI tissue.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. Approval is contingent upon minor edits being made to the application and favorable review by two reviewers and favorable re-review by one reviewer.

36. IBCA00002193_AR02

Guo, Longhua – Renewal

Current approval: BSL1 (vectorless systems); ABSL1 (flatworms and lizards administered vectorless systems). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: Added work with plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

Motion: Janet Follo motioned to approve the (4) IBC applications listed above at the containment levels agreed upon.

Second: Huiru Kopera seconded the motion.

Vote: All in favor

6. Matters Arising

There were no matters arising.